tifenazoxide
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 19, 2001 (NCT00400283)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Sulfonylurea receptor 1INHIBITOR
ABCC8 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC1(NC2=NS(=O)(=O)c3sc(Cl)cc3N2)CC1- Mol. weight
- 291.79 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL135191 ↗
Also known as
- tifenazoxide
- tifenazoxide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04744129 | N/A | Aug 31, 2021 | University of Copenhagen |
| NCT00400283 | Phase 1 | Jan 19, 2001 | Novo Nordisk |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 1 | 1 | 1 | 2001 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1